Status:
ACTIVE_NOT_RECRUITING
Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
Lead Sponsor:
Kumamoto University
Conditions:
Coronary Artery Disease
End Stage Renal Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate wh...
Detailed Description
Patients on hemodialysis for end-stage renal disease are at high risk for death from ischemic heart disease. It was reported that nicorandil, a hybrid compound on adenosine triphosphate-sensitive pota...
Eligibility Criteria
Inclusion
- Eligible patients are who meet the following criteria:
- Patient with previously diagnosed coronary artery disease (significant coronary artery stenosis is defined as \> 75% narrowing of the artery lumen)
- Patients who continued hemodialysis for more than one month
Exclusion
- Within one month after acute myocardial infarction
- Within 3 months after coronary artery bypass graft (CABG)
- Treatment with phosphodiesterase type 5 inhibitor
- Candidates for carotid artery stenting
- Severe disease requiring active medical treatment
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2026
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT01475123
Start Date
June 1 2008
End Date
March 1 2026
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan, 860-8556